Analysts See 30% Growth Ahead for Boston Scientific

Boston Scientific (BSX) is drawing sustained bullish sentiment from analysts who are projecting roughly 30% year-over-year earnings or revenue growth by 2026, a pace that would materially outstrip the broader medical device sector. The optimism appears rooted in the company's expanding product portfolio and execution track record, though the specific growth drivers cited vary across analyst reports. At that growth rate, BSX would be repricing relative to med-tech peers whose forward multiples have compressed on rate and reimbursement pressures. The key variable to monitor is whether organic volume growth or margin expansion is carrying the projection, as each implies a different risk profile for the stock. Investors will be watching upcoming earnings calls and guidance revisions for hard data points that either validate or stress-test the 30% target. Any shortfall in product launch cadence or pricing power in key segments could quickly shift the consensus tone.